Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Stempeutics Research

Tracked across 1 events · 6 articles · First seen Sep 10, 2026 · Last active Sep 10, 2026

Sentiment
25
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 25
Tech
India's India — Drugs Controller General of India (DCGI) has approved an allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis, marking the first time such an approved regenerative therapy enters clinical practice in…
Impact: Stempeutics Research manufactures the DCGI-approved stem cell therapy, making it a key beneficiary of the first approved regenerative knee osteoarthritis treatment in India. The approval strengthens its position in the regenerative medicine market.
Sep 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Stempeutics Research live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.